James M. Cornelius - Sep 16, 2024 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)

Role
Director
Signature
/s/ Richard Bartram, attorney-in-fact
Stock symbol
MBX
Transactions as of
Sep 16, 2024
Transactions value $
$0
Form type
4
Date filed
9/17/2024, 08:11 PM
Previous filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBX Common Stock Conversion of derivative security +102K 102K Sep 16, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBX Series A Convertible Preferred Stock Conversion of derivative security -994K -100% 0 Sep 16, 2024 Common Stock 82.7K Direct F1
transaction MBX Series B Convertible Preferred Stock Conversion of derivative security -233K -100% 0 Sep 16, 2024 Common Stock 19.4K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.